A phase I/II study of Bcl-2 antisense oligonucleotide (Genasense) [oblimersen] in combination with doxorubicin and docetaxel in metastatic and locally advanced breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2014
At a glance
- Drugs Oblimersen (Primary) ; Docetaxel; Doxorubicin
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.